Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping

Patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping can benefit from crizotinib treatment. Currently, the main resistance mechanisms to crizotinib are MET D1228N and Y1230C mutations. We reported a case of a Chinese NSCLC patient with MET exon 14 skipping detected by targ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Ding, Guanggui, Wang, Jian, Ding, Peikun, Wen, Yuxin, Yang, Lin
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2019
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6606013/
https://ncbi.nlm.nih.gov/pubmed/30744539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2019.1566049
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados